India's Dr. Reddy's Laboratories has indicated that the supply disruption for semaglutide will persist at least until late October. The company's assessment points to ongoing shortages of the widely used diabetes and weight-loss medication.
India-based pharmaceutical company Dr. Reddy's Laboratories has announced that the supply disruption affecting semaglutide is expected to continue for several more months. According to the company's latest estimate, the shortage will last at least until late October of this year. This projection covers the period from the current date through the end of October, with no indication of earlier resolution.
Semaglutide is a glucagon-like peptide-1 GLP-1 receptor agonist used in the treatment of type 2 diabetes and, more recently, for chronic weight management. The medication has seen surging demand globally, leading to periodic supply constraints across multiple manufacturers. Dr. Reddy's, one of the major generic drug producers in India, has been monitoring the situation closely.
The company's statement reflects its current understanding of the supply chain challenges affecting semaglutide. Dr. Reddy's did not provide specific reasons for the disruption in the report, but the extended timeline through late October suggests significant production or distribution bottlenecks. The Indian drugmaker has not indicated whether it expects the shortage to worsen or improve before that date.
This supply disruption could affect patients who rely on semaglutide for glucose control or weight loss. Healthcare providers may need to consider alternative treatments or adjust prescription schedules during the shortage period. Dr. Reddy's has not announced any specific mitigation measures or contingency plans as part of its outlook.
The prolonged semaglutide supply disruption comes amid broader global demand for GLP-1 receptor agonists. Dr. Reddy's is among several companies involved in the production and distribution of these medications. The company's forecast for a shortage lasting until at least late October underscores the ongoing challenges in meeting patient needs.
While Dr. Reddy's did not comment on whether other manufacturers face similar timelines, the company's assessment applies specifically to its own supply chain and market involvement. The situation may change if new supply sources become available or if production capacity increases before the stated date. For now, the company advises stakeholders to plan for the disruption to continue through October.
The key takeaway from Dr. Reddy's announcement is the minimum duration: at least through late October. This date is not a guarantee of resolution but rather the earliest point at which the company currently expects normal supply to resume. Patients and prescribers should be prepared for possible delays or shortages beyond that point if conditions do not improve as anticipated.
Peptides referenced: Semaglutide, Glucagon, GLP-1.
Related reading: Dr. Reddy's Halts Generic Semaglutide Supply Over API Issue, GLP-1 Drug Use Among US Adults Reaches 11%, Gallup Poll Shows, FDA Approves Second IGF-1R Antibody for Thyroid Eye Disease, Bachem Holding AG Focuses on Peptide Manufacturing Amid Growing Biotech Demand.